STOCK TITAN

Oramed Pharmaceuticals, Inc - ORMP STOCK NEWS

Welcome to our dedicated news page for Oramed Pharmaceuticals (Ticker: ORMP), a resource for investors and traders seeking the latest updates and insights on Oramed Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Oramed Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Oramed Pharmaceuticals's position in the market.

News
Rhea-AI Summary
Oramed Pharmaceuticals Inc. announces the initiation of a Phase 3 oral insulin trial in the United States under a new protocol, a JV with Chinese partner HTIT, Scilex Senior Secured Note, and PeriTech Asset Purchase & Strategic Out-licensing. Oramed is focusing on enhancing shareholder value through various strategic initiatives.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.32%
Tags
none
-
Rhea-AI Summary
PhaseV, a pioneer in causal machine learning (ML) technology for clinical trials, has raised $15 million in funding. The company's ML-driven adaptive process can significantly accelerate the clinical drug development process and increase certainty, resulting in more efficient and successful trials.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.52%
Tags
-
Rhea-AI Summary
Sorrento Therapeutics completes sale of securities to Scilex Holding Company for $110 million, losing controlling interest over Scilex. Oramed SPA terminated.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.14%
Tags
none
Rhea-AI Summary
Oramed and Scilex entered into a Securities Purchase Agreement, replacing Oramed's previous agreements with Sorrento Therapeutics. Scilex issued a Senior Secured Promissory Note to Oramed, with an initial principal balance of $101,875,000.00 and an 18-month maturity. Oramed also received warrants to purchase up to 17 million shares of Scilex common stock. The Note has an interest rate of SOFR plus 8.5% and repayment will begin on December 21, 2023. Oramed CEO believes this is a favorable outcome for both companies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.14%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.23%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.64%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.22%
Tags
conferences
-
Rhea-AI Summary
Oramed Pharmaceuticals Inc. announced that its strategic partner, Hefei Tianhui Biotechnology, has completed Phase 3 trials of oral insulin in China and is moving towards regulatory approval. Oramed has also completed an analysis of its U.S.-based Phase 3 trial, finding that subpopulations of patients with specific parameters responded well to oral insulin, showing a significant reduction in HbA1c levels.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.6%
Tags
-
Rhea-AI Summary
Oramed Pharmaceuticals appoints Benjamin Shapiro to its Board of Directors. Mr. Shapiro is a successful entrepreneur and media professional. He owns over 4% of Oramed's stock. His addition is expected to bring value to the company and its shareholders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.53%
Tags
management
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.77%
Tags
none
Oramed Pharmaceuticals, Inc

Nasdaq:ORMP

ORMP Rankings

ORMP Stock Data

102.11M
36.70M
11.23%
13.88%
1.44%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
New York

About ORMP

oramed pharmaceuticals (nasdaqcm:ormp) is developing proprietary technology for the oral delivery of drugs presently administered by way of injection. through its patented flagship product, an orally ingestible insulin capsule currently in phase 2 trials under the usfda, the company is seeking to revolutionize the treatment of diabetes. read more: http://www.oramed.com/investors/corporate-presentation watch: https://www.youtube.com/watch?v=5qchxtdv9eg